Originally identified as a proto‐oncogene in B‐cell lymphomas, BCL6 drives malignant phenotypes by repressing proliferation and DNA damage checkpoints, as well as by blocking terminal B‐cell differentiation [42]. Here, BCL6 is linked to B-cell non-Hodgkin lymphoma.